




CV Template of KATRD International Conference 2021

Name	Yoshikazu Inoue			
First Name	Yoshikazu	Last Name	Inoue	
Country	Japan			
Organization	National Hospital Organization Kinki-Chuo Chest Medical Center			
Current Position	Executive Director, Clinical Research Center			

Educational Background

1977-1983	Ehime University, School of Medicine (M.D.)
1984-1988	Graduate School, Ehime University, School of Medicine (Ph.D.)
1988-1991	Department of Internal Medicine, Respiratory Medicine, National Ehime Hospital
1991-1997	Acting Assistant Professor, the 2nd Department of Internal Medicine Ehime University, School of Medicine
1994-1997	Post graduate fellow, University of Colorado, Health Science Center, National Jewish Center for Immunology and Respiratory Medicine, Occupational and Environmental Section, Pulmonary Division (Denver, Colorado, USA)
1997-1998	Chief Physician, Internal Medicine, National Kinki-Chuo Hospital for Chest Diseases, Osaka, Japan
1998-2001	General Manager, Immunology Laboratory, Department of Clinical Research, and Chief Physician, Internal Medicine, National Kinki-Chuo Hospital for Chest Diseases, Osaka, Japan
2001-2004	Director of Department of Respiratory Failure, Clinical Research Center, National Kinki-Chuo Hospital for Chest Diseases, Osaka, Japan
2004	Director of Department of Diffuse Lung Diseases and Respiratory Failure, Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center
2006-2011	Invited Associate Professor, Infection, Immunology and Oncology Cooperating Course, Graduate School of Medicine, Osaka University, Osaka, Japan
2011-	Invited Professor, Infection, Immunology and Oncology Cooperating Course, Graduate School of Medicine, Osaka University, Osaka, Japan
2014-	Executive Director, Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center Director, Department of Intractable Lung Diseases (Interstitial Lung Diseases), Head, Division of Tuberculosis Vaccine and Treatment National Hospital Organization Kinki-Chuo Chest Medical Center
2014-	Group Leader of Respiratory Network of National Hospital Organization



Professional Organizations

Fleischner Society: Past-President of the Fleishner Society
American Thoracic Society: Member
European Respiratory Society: Member
Asian-Pacific Society of Respirology: Member
World Association of Sarcoidosis and Other Granulomatous Disorders: Member
Japanese Society of Internal Medicine: Member
Japanese Respiratory Society: Delegate
Japan Society of Sarcoidosis and Other Granulomatous Disorders: President
The Japanese Society for Tuberculosis: Member
Japan Society for Respiratory Endoscopy: Delegate
Japanese Medical Society for Lung Surfactant and Biological Interface: Delegate
The Japanese Circulation Society: Member
Japanese Society of Allergology: Member
The Japan Geriatrics Society: Member

Main Scientific Publications

1. Hirose M, Arai T, Sugimoto C, Takimoto T, Sugawara R, Minomo S, Shintani S, Takeuchi N, Katayama K, Inoue Y, Kagawa T, Kasai T, Akira M, Inoue Y. B cell-activating factors in autoimmune pulmonary alveolar proteinosis. **Orphanet J Rare Dis.** 2021 Mar 2;16(1):115. doi: 10.1186/s13023-021-01755-y.
2. Sakaue S, Yamaguchi E, Inoue Y, Takahashi M, Hirata J, Suzuki K, Ito S, Arai T, Hirose M, Tanino Y, Nikaido T, Ichiwata T, Ohkouchi S, Hirano T, Takada T, Miyawaki S, Dofuku S, Maeda Y, Nii T, Kishikawa T, Ogawa K, Masuda T, Yamamoto K, Sonehara K, Tazawa R, Morimoto K, Takaki M, Konno S, Suzuki M, Tomii K, Nakagawa A, Handa T, Tanizawa K, Ishii H, Ishida M, Kato T, Takeda N, Yokomura K, Matsui T, Watanabe M, Inoue H, Imaizumi K, Goto Y, Kida H, Fujisawa T, Suda T, Yamada T, Satake Y, Ibata H, Hizawa N, Mochizuki H, Kumanogoh A, Matsuda F, Nakata K, Hirota T, Tamari M, Okada Y. Genetic determinants of risk in autoimmune pulmonary alveolar proteinosis. **Nat Commun.** 2021 Feb 15;12(1):1032. doi: 10.1038/s41467-021-21011-y.
3. Inoue Y, Kaner RJ, Guiot J, Maher TM, Tomassetti S, Moiseev S, Kuwana M, Brown KK. Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype. **Chest** 2020, Aug;158(2):646-659
4. Trapnell BC, Inoue Y, Bonella F, Morgan C, Juneau S, Bendstrup E, Campo I, Papis SA, Yamaguchi E, Cetinkaya E, Ilkovich MM, Kramer MR, Veltkamp M, Kreuter M, Baba T, Ganslandt C, Tarnow I, Waterer G, Jouhikainen T; IMPALA Trial Investigators. Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis. **N Engl J Med.** 2020 Oct 22;383(17):1635-1644.
5. Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M, Bargagli E, Chung JH, Collins BF, Bendstrup E, Chami HA, Chua AT, Corte TJ, Dalphin JC, Danoff SK, Diaz-Mendoza J, Duggal A, Egashira R, Ewing T, Gulati M, Inoue Y, Jenkins AR, Johannson KA, Johkoh T, Tamae-Kakazu M, Kitaichi M, Knight SL, Koschel D, Lederer DJ, Mageto Y, Maier LA, Matiz C, Morell F, Nicholson AG, Patolia S, Pereira CA, Renzoni EA, Salisbury ML, Selman M, Walsh SLF, Wuyts WA, Wilson KC. Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. **Am J Respir Crit Care Med.** 2020 Aug 1;202(3):e36-e69.



6. Hatabu H, Hunninghake GM, Richeldi L, Brown KK, Wells AU, Remy-Jardin M, Verschakelen J, Nicholson AG, Beasley MB, Christiani DC, San José Estépar R, Seo J B, Johkoh T, Sverzellati N, Ryerson CJ, Graham Barr R, Goo JM, Austin JHM, Powell CA, Lee KS, Inoue Y, Lynch DA. Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. **Lancet Respir Med.** 2020 Jul;8(7):726-737.
7. Sakaue S, Yamaguchi E, Inoue Y, Takahashi M, Hirata J, Suzuki K, Ito S, Arai T, Hirose M, Tanino Y, Nikaido T, Ichiwata T, Ohkouchi S, Hirano T, Takada T, Miyawaki S, Dofuku S, Maeda Y, Nii T, Kishikawa T, Ogawa K, Masuda T, Yamamoto K, Sonehara K, Tazawa R, Morimoto K, Takaki M, Konno S, Suzuki M, Tomii K, Nakagawa A, Handa T, Tanizawa K, Ishii H, Ishida M, Kato T, Takeda N, Yokomura K, Matsui T, Watanabe M, Inoue H, Imaizumi K, Goto Y, Kida H, Fujisawa T, Suda T, Yamada T, Satake Y, Ibata H, Hizawa N, Mochizuki H, Kumanogoh A, Matsuda F, Nakata K, Hirota T, Tamari M, Okada Y. Genetic determinants of risk in autoimmune pulmonary alveolar proteinosis. **Nat Commun.** 2021 Feb 15;12(1):1032
8. Johkoh T, Lee KS, Nishino M, Travis WD, Ryu JH, Lee HY, Ryerson CJ, Franquet T, Bankier AA, Brown KK, Goo JM, Kauczor HU, Lynch DA, Nicholson AG, Richeldi L, Schaefer-Prokop CM, Verschakelen J, Raouf S, Rubin GD, Powell C, Inoue Y, Hatabu H. Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society. **Chest.** 2021 Mar;159(3):1107-1125.
9. Geoffrey D. Rubin, Christopher J. Ryerson, Linda B. Haramati, Nicola Sverzellati, Jeffrey P. Kanne, Suhail Raouf, Neil W. Schluger, Annalisa Volpi, Jae-Joon Yim, Ian B. K. Martin, Deverick J. Anderson, Christina Kong, Talissa Altes, Andrew Bush, Sujal R. Desai, Jonathan Goldin, Jin Mo Goo, Marc Humbert, Yoshikazu Inoue, Hans-Ulrich Kauczor, Fengming Luo, Peter J. Mazzone, Mathias Prokop, Martine Remy-Jardin, Luca Richeldi, Cornelia M. Schaefer-Prokop, Noriyuki Tomiyama, Athol U. Wells, Ann N. Leung. The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. **Chest.** 2020 Apr 7 doi: 10.1016/j.chest.2020.04.003 [Epub ahead of print].
10. Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresima M, Goeldner RG, Schlenker-Herceg R, Kolb M; INBUILD trial investigators.. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. **Lancet Respir Med.** 2020 Mar 5. pii: S2213-2600(20)30036-9.
11. Liu H, Osterburg AR, Flury J, Swank Z, McGraw DW, Gupta N, Wikenheiser-Brockamp KA, Kumar A, Tazi A, Inoue Y, Hirose M, McCormack FX, Borchers MT.. MAPK mutations and cigarette smoke promote the pathogenesis of pulmonary Langerhans cell histiocytosis. **JCI Insight.** 2020 Feb 27;5(4). pii: 132048.
12. Tazawa R, Ueda T, Abe M, Tatsumi K, Eda R, Kondoh S, Morimoto K, Tanaka T, Yamaguchi E, Takahashi A, Oda M, Ishii H, Izumi S, Sugiyama H, Nakagawa A, Tomii K, Suzuki M, Konno S, Ohkouchi S, Tode N, Handa T, Hirai T, Inoue Y, Arai T, Asakawa K, Sakagami T, Hashimoto A, Tanaka T, Takada T, Mikami A, Kitamura N, Nakata K. Inhaled GM-CSF for Pulmonary Alveolar Proteinosis. **N Engl J Med.** 2019 Sep 5;381(10):923-932